Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG.
Dimopoulos MA, et al. Among authors: belch a.
Blood Cancer J. 2020 Sep 4;10(9):91. doi: 10.1038/s41408-020-00357-4.
Blood Cancer J. 2020.
PMID: 32887873
Free PMC article.
Clinical Trial.